Ozempic vs. Zepbound
Ozempic and Zepbound are both semaglutide-based GLP-1 receptor agonists, but Zepbound also includes a GIP receptor agonist. Their primary uses differ slightly. Ozempic is approved for type 2 diabetes management and cardiovascular risk reduction, while Zepbound focuses on chronic weight management. Ozempic delivers significant HbA1c reductions and moderate weight loss, while Zepbound shows promise for potential greater weight lossNeither drug has significant off-label uses. Common side effects, including nausea, overlap, along with serious risks like pancreatitis. Ozempic costs $875/month, while Zepbound’s cost $1,125/month. Neither drug currently faces shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions